The historical rank and industry rank for Genomma Lab InternacionalB de CV's EV-to-OCF or its related term are showing as below:
MEX:LABB'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.91 Med: 13.35 Max: 43.5
Current: 9.9
During the past 13 years, the highest EV-to-OCF of Genomma Lab InternacionalB de CV was 43.50. The lowest was 6.91. And the median was 13.35.
MEX:LABB's EV-to-OCF is ranked better than 51.29% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.415
vs MEX:LABB: 9.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genomma Lab InternacionalB de CV (MEX:LABB) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genomma Lab InternacionalB de CV's PE Ratio (TTM) for today is calculated as:
Genomma Lab InternacionalB de CV's share price for today is MXN15.33.
Genomma Lab InternacionalB de CV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1.644.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genomma Lab InternacionalB de CV EV-to-OCF Related Terms
Genomma Lab InternacionalB de CV EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's EV-to-OCF falls into.
Genomma Lab InternacionalB de CV's current Enterprise Value is MXN19,562 Mil.
Genomma Lab InternacionalB de CV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,976 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a EV-to-OCF of 9.90 as of Jul. 06, 2026. This is 26% below median its historical median of 13.35. Over the past decade, Genomma Lab InternacionalB de CV's EV-to-OCF has ranged from 6.91 to 43.50. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #491 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 48.7%.
Is Genomma Lab InternacionalB de CV's EV-to-OCF too high?
Genomma Lab InternacionalB de CV's current EV-to-OCF of 9.90 is 26% below median its 10-year median of 13.35. Over the past 10 years, this metric has ranged from a low of 6.91 to a high of 43.50. The Drug Manufacturers industry median EV-to-OCF is 10.42. Genomma Lab InternacionalB de CV's value of 9.90 is 4.9% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #491 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #491 out of 1008 companies for EV-to-OCF. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. The industry median EV-to-OCF is 10.42. Genomma Lab InternacionalB de CV's value of 9.90 is 4.9% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own EV-to-OCF has ranged from 6.91 to 43.50 over the past decade. While the company's 10-year median is 13.35 vs. the industry median of 10.42, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.42, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current EV-to-OCF of 9.90 is 4.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current EV-to-OCF is 9.90, which is 26% below median its own 10-year median of 13.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.67, compared to a current price of MXN15.33 — trading 13.2% below its estimated fair value. The current EV-to-OCF is 9.90, which is 26% below median its 10-year median of 13.35 and 4.9% below the Drug Manufacturers industry median of 10.42. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current EV-to-OCF is 9.90 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.33 is trading 13.2% below its estimated GF Value™ of MXN17.67.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
EV-to-OCF: 9.90 (26% below median its 10-year median of 13.35)
GF Value™: MXN17.67 vs. price of MXN15.33 (13.2% below fair value)
Industry Position: 4.9% below the Drug Manufacturers median (#491 of 1008)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
